Anti-cancer Peptides from Ras-P21 and P53 Proteins

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|17|25|2677-2698

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.17, Iss.25, 2011-08, pp. : 2677-2698

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A mutated p53 status did not prevent the induction of apoptosis by sulforaphane, a promising anti-cancer drug

By Fimognari Carmela   Sangiorgi Luca   Capponcelli Silvia   Nüsse Michael   Fontanesi Silvia   Berti Fausto   Soddu Silvia   Cantelli-Forti Giorgio   Hrelia Patrizia  

Investigational New Drugs, Vol. 23, Iss. 3, 2005-06 ,pp. : 195-203

Springer Publishing Company

Access to resources Recommend Favorite

p53: Fighting Cancer

By  

Current Cancer Drug Targets, Vol. 4, Iss. 5, 2004-08 ,pp. : 385-402

Bentham Science Publishers

Access to resources Recommend Favorite

The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs

By  

Current Cancer Drug Targets, Vol. 12, Iss. 2, 2012-02 ,pp. : 85-96

Bentham Science Publishers

Access to resources Recommend Favorite

ALTERATIONS OF K-ras AND p53 MUTATIONS IN COLORECTAL CANCER PATIENTS IN CENTRAL EUROPE

By König Edwin A.   Köves István   Răşinariu Angela   Popp Anghel R.   Kusser Wolfgang C.   Soyonki Ken   Kovács Ágota   Glickman Barry W.   Jeney Andrá   Marcsek Zoltán L.  

Journal of Toxicology and Environmental Health, Vol. 62, Iss. 5, 2001-03 ,pp. : 333-347

Taylor & Francis Ltd

Access to resources Recommend Favorite

Molecular Modeling Approaches in the Discovery of New Drugs for Anti-Cancer Therapy: The Investigation of p53-MDM2 Interaction and its Inhibition by Small Molecules

By  

Current Medicinal Chemistry, Vol. 17, Iss. 28, 2010-09 ,pp. : 3142-3154

Bentham Science Publishers

Access to resources Recommend Favorite